To the Editor:
The diagnostic approach to abnormalities of primary hemostasis is still a major challenge for clinical laboratories. In clinical practice, the investigation of unexplained bleeding ideally uses easy, reliable, and inexpensive screening tests, eventually followed by second-line analyses (1 ) . Because of a lack of reliable alternatives, the bleeding time (BT) test has been widely used for decades. However, the BT test is relatively insensitive and nonspecific with respect to identifying abnormalities of primary hemostasis. The diagnostic efficiency of the BT test for prediction of abnormal perioperative bleeding has been critically questioned (2) (3) (4) (5) , suggesting the need for alternatives.
The interaction of citrated whole blood with biochemically active membranes coated with physiologic agonists (collagen and adenosine diphosphate or collagen and epinephrine) can be used to trigger platelet activation under high shear rates and generate a stable platelet plug. Abnormal prolongation of clot development can be automatically recorded by the PFA-100 ® Analyzer (Dade), which reflects potential qualitative and quantitative abnormalities of platelet function. The clinical usefulness of this test has been studied in some clinical settings, including evaluation of uremia, the laboratory approach to the diagnosis of von Willebrand disorder and platelet dysfunction, and the monitoring of therapy with antiplatelet drugs (6 -8 ) . The within-and day-to-day (total) imprecision (CV) of the test are reportedly Ͻ10% (8 ) . The test may be especially useful in children (9 ) because the analysis does not require the active cooperation of the patient and uses Ͻ2 mL of blood. We agree with Lehman et al. (5 ) on the limited clinical impact of discontinuing the BT test, and we believe that automated, in vitro analyzers can be useful for the identification of some defects of primary hemostasis. The PFA-100 analysis has replaced the BT test in the evaluation of disorders of primary hemostasis in our laboratory (9 ) . 
